Should a Preschool Child with Acute Episodic Wheeze be Treated with Oral Corticosteroids? A Pro/Con Debate

Avraham Beigelman, Sandy Durrani, Theresa W. Guilbert*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Traditionally, preschool-aged children with an acute wheezing episode have been treated with oral corticosteroids (OCSs) based on the efficacy of OCSs in older children and adolescents. However, this practice has been recently challenged based on the results of recent studies. The argument supporting the use of OCSs underscores the observation that many children with recurrent preschool wheezing develop atopic disease in early life which predicts both an increased risk to develop asthma in later life and response to OCS therapy. Further, review of the literature demonstrates heterogeneity of study designs, OCS dosage, interventions, study medication adherence, and settings and overall lack of predefined preschool wheezing phenotypes. The heterogeneity of these studies does not allow a definitive recommendation discouraging OCS use. Advocates against the use of OCSs in this population argue that most of studies investigating the efficacy of OCSs in acute episodic wheeze in preschool-aged children have not demonstrated beneficial effects. Moreover, repeated OCS bursts may be associated with adverse effects. Finally, both sides can agree that there is a significant need to conduct efficacy trials evaluating OCS treatment in preschool-aged children with recurrent wheezing targeted at phenotypes that would be expected to respond to OCSs. This article presents a summary of recent literature regarding the use of OCSs for acute episodic wheezing in preschool-aged children and a "pro" and "con" debate for such use.

Original languageEnglish
Pages (from-to)27-35
Number of pages9
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume4
Issue number1
DOIs
StatePublished - 1 Jan 2016
Externally publishedYes

Funding

FundersFunder number
CF Foundation Therapeutics
City Asthma Consortium
CompleWare Corporation
ICAC
KaloBios
UW Madison Medical and Education Research Committee
National Institutes of Health
U.S. Department of Health and Human Services
National Heart, Lung, and Blood Institute
National Institute of Allergy and Infectious Diseases
Abbott Laboratories
GlaxoSmithKline
Teva Pharmaceutical Industries
F. Hoffmann-La Roche
American Board of Pediatrics
Forest Research Institute
MedImmune

    Fingerprint

    Dive into the research topics of 'Should a Preschool Child with Acute Episodic Wheeze be Treated with Oral Corticosteroids? A Pro/Con Debate'. Together they form a unique fingerprint.

    Cite this